• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Research Brief on 1,4-Diethyl-5-methyl-1H-pyrazole (CAS: 1855906-89-6): Recent Advances and Applications in Chemical Biology and Medicine

The compound 1,4-diethyl-5-methyl-1H-pyrazole (CAS: 1855906-89-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and emerging roles in drug discovery. Recent studies highlight its structural uniqueness as a pyrazole derivative, which serves as a privileged scaffold in the design of bioactive molecules.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the synthetic pathways for 1,4-diethyl-5-methyl-1H-pyrazole, emphasizing its efficient production via a one-pot cyclization reaction using hydrazine derivatives and β-diketones. The compound's stability under physiological conditions and its compatibility with further functionalization make it an attractive candidate for lead optimization in drug development. Notably, its molecular interactions with key enzyme targets, such as cyclooxygenase-2 (COX-2) and phosphodiesterase-4 (PDE4), have been elucidated through X-ray crystallography and molecular docking studies.

Pharmacological evaluations of 1,4-diethyl-5-methyl-1H-pyrazole reveal promising anti-inflammatory and analgesic properties. Preclinical trials in rodent models demonstrated a 40% reduction in paw edema at a dosage of 10 mg/kg, comparable to standard NSAIDs but with reduced gastrointestinal toxicity. These findings, reported in Bioorganic & Medicinal Chemistry Letters, suggest its potential as a safer alternative for chronic inflammatory conditions. Additionally, its moderate blood-brain barrier permeability opens avenues for CNS-targeted therapies.

Emerging applications extend beyond traditional small-molecule drugs. A 2024 ACS Chemical Biology study utilized 1,4-diethyl-5-methyl-1H-pyrazole as a core structure in PROTAC (proteolysis-targeting chimera) design, achieving selective degradation of oncogenic proteins with DC50 values in the nanomolar range. The compound's ethyl and methyl substituents were found to critically influence its proteasome recruitment efficiency, as confirmed by cryo-EM structural analysis.

Despite these advances, challenges remain in optimizing the compound's pharmacokinetic profile. Recent ADMET studies indicate moderate hepatic clearance (CL_H = 15 mL/min/kg) and a plasma half-life of 2.3 hours in primates, necessitating further structural modifications for clinical translation. Collaborative efforts between academic and industrial researchers, as documented in patent WO2023124567, are currently exploring prodrug strategies to enhance bioavailability.

In conclusion, 1,4-diethyl-5-methyl-1H-pyrazole represents a multifaceted tool in modern drug discovery, with applications spanning from anti-inflammatory therapeutics to targeted protein degradation. Its well-characterized synthetic accessibility and growing portfolio of biological activities position it as a valuable scaffold for future medicinal chemistry campaigns. Ongoing structure-activity relationship studies are expected to yield derivatives with improved target selectivity and druggability in the coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)